News

Video

Dr Facon on the Efficacy of Isa-VRd in Newly Diagnosed Multiple Myeloma

Conference|ASCO Annual Meeting

Thierry Facon, MD, discusses findings from the phase 3 IMROZ trial investigating Isa-VRd in patients with newly diagnosed multiple myeloma.

Thierry Facon, MD, professor, hematology, Department of Hematology, Lille University Hospital, discusses findings from the phase 3 IMROZ trial (NCT03319667) investigating isatuximab (Sarclisa) plus bortezomib, lenalidomide (Revlimid), and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma.

Related Videos
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD
Janaki Neela Sharma, MD
Karine Tawagi, MD,
Vered Stearns, MD
Related Content
Katsyarina – stock.adobe.com
December 3rd 2024

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tislelizumab Plus Chemo for Advanced Gastric/GEJ Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
November 27th 2024

EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Penpulimab Plus Anlotinib for Advanced HCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 26th 2024

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

Health Canada Approves Cilta-Cel in Myeloma
November 26th 2024

Health Canada Approves Cilta-Cel for Relapsed/Lenalidomide-Refractory Myeloma